DA
IMRX icon

DCF Advisers’s Immuneering IMRX Stock Holding History

DCF Advisers’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$746K Sell
141,462
-73,538
-34% -$377K 0.2% 65
2025
Q4 		$1.41M Buy
+215,000
New +$1.38M 0.38% 59

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DCF Advisers's IMRX Position: Q1 2026 in Review

DCF Advisers reduced its Immuneering (IMRX) stake by 34% in Q1 2026, selling an estimated $377K and leaving 141,462 shares worth $746K. The position accounts for 0.2% of the portfolio, ranked #65.

DCF Advisers first reported a position in IMRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.41M in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • DCF Advisers held 141,462 shares of Immuneering worth $746K as of Q1 2026.
  • DCF Advisers sold 73,538 Immuneering shares in Q1 2026, an estimated $377K.
  • Immuneering made up 0.2% of DCF Advisers's portfolio in Q1 2026, its #65 holding.
  • DCF Advisers first reported a position in Immuneering in Q4 2025 and has held it in 2 quarters since.
  • DCF Advisers's Immuneering position peaked at $1.41M in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.